MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/105/0.1/20.12.24 | Market Closed - Börse Stuttgart 17:51:12 05/07/2024 BST | ||
| 3.77 EUR | +3.57% |
|
| Current month | -5.28% | ||
| 3 months | +38.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 3.77 | +3.57% |
| 04/07/24 | 3.64 | +4.90% |
| 03/07/24 | 3.47 | -10.10% |
| 02/07/24 | 3.86 | -6.54% |
| 01/07/24 | 4.13 | +3.77% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 05:51 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GAC |
| ISIN | DE000ME1GAC0 |
| Date issued | 03/10/2023 |
| Strike | 105 $ |
| Maturity | 20/12/2024 (168 Days) |
| Parity | 10 : 1 |
| Emission price | 0.95 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.23 € |
|---|---|
| Lowest since issue | 0.73 € |
| Spread | 0.01 € |
| Spread % | 0.26% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
974
DKK
Average target price
952.2
DKK
Spread / Average Target
-2.24%
- Stock Market
- Warrants
- Warrant
